Robocash Group results for H1 2022

Robocash Group is pleased to share the results for the six-month period of 2022. As the product line expands, the holding increases issuance volumes while maintaining a low-risk profile. The data is compliant with the International Financial Reporting Standards (IFRS).

Here are key group highlights:

  • The revenue for the period amounts to 214.9 M USD, up by 53.6%.
  • The net profit stands at 13.9 M USD, 9.7% less than the same period previous year. As the Group continues developing its eCommerce products in the Philippines, there is a decrease in net profit compared to previous periods. However, this effect stays strictly within the Management's estimates, and the holding continues to show positive results.
  • Both total assets and total equity increased by +89.65% and +86.6%, respectively, compared to H1 2021.
  • From the end of 2021, the retained earnings have grown to 58.7 M USD, up by 71.6%.

Group milestones and achievements

  • Kazakhstan over-fulfilled the planned budget, exceeding group initial H1 net profit estimates by 409%
  • The Group has launched the first ever medicine aggregator service in the Philippines called UnaPharma. The service allows customers to reserve medication for pick-up in any of the partnered pharmacies. Beginning now with reservations, in the future the company aims to offer same-day medicine delivery, a health hotline, online prescription services, and more.
  • The Group’s short-term loans service in the Philippines now offers a consumer credit line for returning customers. Filipino borrowers may now take longer-term loans with split payments. 

Robocash d.o.o (“Robocash”) is a company registered in the Republic of Croatia under registration No. 081224371, with legal address at Petračiceva 4, Zagreb, Croatia, 10110.

Robocash is not regulated under any financial services license. When you invest on Robocash, you buy claim rights for loan receivables and investments in loan receivables are subject to risks. We advise diversifying investments and carefully evaluating the risks.